search
Back to results

Addition of Popliteal Plexus Block to Continuous Femoral Nerve Block for Total Knee Arthroplasty

Primary Purpose

Pain, Postoperative

Status
Unknown status
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Ropivacaine 0.5% Injectable Solution
Ropivacaine 0.5% Injectable Solution
Ropivacaine 0.5% Injectable Solution
Sponsored by
University Hospital, Geneva
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients scheduled for total knee athroplasty under general anesthesia
  • ASA 1-3

Exclusion Criteria:

  • Kidney disease with GFR < 50 ml/mn
  • Daily opioid consumption > 1 month
  • Allergy to local anesthetics
  • Neurological problems of the lower extremity
  • other contraindications to peripheral nerve blocks

Sites / Locations

  • Departement of Anesthesia, Hôpitaux Universitaires de GenèveRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Popliteal plexus block and continuous femoral nerve block

continuous femoral nerve block

Arm Description

Outcomes

Primary Outcome Measures

Total iv morphine consumption (mg)

Secondary Outcome Measures

Total iv morphine consumption (mg)
Average and maximum pain scores (Numeric rating scale 0-10)
Sciatic extension of popliteal plexus block
Presence of sensitive or/and motor sciatic extension of popliteal plexus block
Plantarflexion and dorsiflexion ankle strength (Newtons)
Knee pain localization (anterior, internal, posterior, lateral, medial)
Popliteal plexus block procedure time (minutes)
Onset of action = beginning of the disinfection; End of action = end of injection of 15 mls of Ropivacain 0.5%
Popliteal plexus block duration of action (hours)
Onset of action = Time from end of infection of 15 mls of Ropivacain 0.5%; End of action = onset of lateral and/or posterior knee pain (With Numeric rating scale ≥ 4)

Full Information

First Posted
July 27, 2019
Last Updated
August 6, 2019
Sponsor
University Hospital, Geneva
search

1. Study Identification

Unique Protocol Identification Number
NCT04048889
Brief Title
Addition of Popliteal Plexus Block to Continuous Femoral Nerve Block for Total Knee Arthroplasty
Official Title
Addition of Popliteal Plexus Block to Continuous Femoral Nerve Block for Total Knee Arthroplasty
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Unknown status
Study Start Date
July 22, 2019 (Actual)
Primary Completion Date
March 1, 2022 (Anticipated)
Study Completion Date
July 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Geneva

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The popliteal plexus block has been described as an alternative analgesic postoperative pain treatment for total knee arthroplasty. It consists of injecting local anaeshetics inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle, in order to anesthetize the popliteal plexus. However, the analgesic efficacy has never been demonstrated in a randomized controlled trial. Therefore the objective of this study is to investigate the analgesic benefit of this block combined with a continuous femoral nerve block, on patients scheduled for total knee athroplasty.
Detailed Description
Patients scheduled to undergo total knee arthroplasty under general anesthesia will be randomly allocated to two groups: continuous femoral nerve block alone or continuous femoral nerve block with addition of a popliteal plexus block. The continuous femoral nerve block will be performed by the anesthesiologist with 15 mLs of ropivacaine 0.5%, under ultrasound guidance before the beginning of the general anesthesia. The popliteal plexus block will be done by the anesthesiology, under ultrasound guidance, before the beginning of the surgery, under general anesthesia. Postoperative analgesia will include acetaminophen (4 x 1000 mg), ibuprofen (3 x 400 mg) and a continuous infusion of Ropivacaine 0.2%.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled triple-blinded trial
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
66 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Popliteal plexus block and continuous femoral nerve block
Arm Type
Experimental
Arm Title
continuous femoral nerve block
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Ropivacaine 0.5% Injectable Solution
Other Intervention Name(s)
Continous femoral nerve block
Intervention Description
Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
Intervention Type
Drug
Intervention Name(s)
Ropivacaine 0.5% Injectable Solution
Other Intervention Name(s)
Continous femoral nerve block
Intervention Description
Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
Intervention Type
Drug
Intervention Name(s)
Ropivacaine 0.5% Injectable Solution
Other Intervention Name(s)
Popliteal plexus block
Intervention Description
Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
Primary Outcome Measure Information:
Title
Total iv morphine consumption (mg)
Time Frame
12 postoperative hours
Secondary Outcome Measure Information:
Title
Total iv morphine consumption (mg)
Time Frame
24 and 48 postoperative hours
Title
Average and maximum pain scores (Numeric rating scale 0-10)
Time Frame
12, 24 and 48 postoperative hours
Title
Sciatic extension of popliteal plexus block
Description
Presence of sensitive or/and motor sciatic extension of popliteal plexus block
Time Frame
2 and 24 postoperative hours
Title
Plantarflexion and dorsiflexion ankle strength (Newtons)
Time Frame
2 and 24 postoperative hours
Title
Knee pain localization (anterior, internal, posterior, lateral, medial)
Time Frame
2, 12, 24 and 48 postoperative hours
Title
Popliteal plexus block procedure time (minutes)
Description
Onset of action = beginning of the disinfection; End of action = end of injection of 15 mls of Ropivacain 0.5%
Time Frame
When performing the popliteal plexus block
Title
Popliteal plexus block duration of action (hours)
Description
Onset of action = Time from end of infection of 15 mls of Ropivacain 0.5%; End of action = onset of lateral and/or posterior knee pain (With Numeric rating scale ≥ 4)
Time Frame
up to 48 postoperative hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients scheduled for total knee athroplasty under general anesthesia ASA 1-3 Exclusion Criteria: Kidney disease with GFR < 50 ml/mn Daily opioid consumption > 1 month Allergy to local anesthetics Neurological problems of the lower extremity other contraindications to peripheral nerve blocks
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kevin Stebler, MD
Phone
0041795532149
Email
kevin.stebler@hcuge.ch
Facility Information:
Facility Name
Departement of Anesthesia, Hôpitaux Universitaires de Genève
City
Geneva
ZIP/Postal Code
1205
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kevin Stebler, MD
Phone
0041795532149
Email
kevin.stebler@hcuge.ch
First Name & Middle Initial & Last Name & Degree
Roxane Fournier, PD
Phone
0041795532058
Email
roxabe.fournier@hcuge.ch

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Addition of Popliteal Plexus Block to Continuous Femoral Nerve Block for Total Knee Arthroplasty

We'll reach out to this number within 24 hrs